Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors. - Ruan DY; Lin SY; Huang JJ; Li YH; Li N; Qu XJ; Du XB; Yin YM; Yuan ZY; Shi YX; Xu F; An X; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2026)